Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEC3-VEN-HHT for newly diagnosed core-binding factor or RUNX1::RUNX1T1 acute myeloid leukemia
ChiCTR2500101192Phase 2Recruiting
- Sponsor
- Tai'an City Central Hospital
- Start
- Apr 2025
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, decitabine and homoharringtonine in acute myeloid leukemia (AML), sponsored by Tai'an City Central Hospital. Primary endpoints: Complete remission rate and Complete remission with incomplete hematologic recovery. Started Apr 2025; status: recruiting.
02
Drugs
venetoclaxdecitabinehomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500101192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101192.